Results from a recent clinical trial indicate that denosumab delayed the spread of prostate cancer metastases bones, however it did not prolong the lives of men. […]
Although some people have called it intriguing, a new “On The Horizon” drug, XL-184, is still very early in its testing. What makes LX184 intriguing is the just released results from a conference in Berlin. In very early testing, 19 of 20 men in a phase I trial showed an improvement in their scans used [...]
A phase III study released at the ASCO meeting demonstrated that for men with bone metastases from prostate cancer, denosumab was more effective than Zometa® (zoledronic acid) at delaying or preventing bone complications such as fracture. […]
According to a new position paper from the North American Menopause Society (NAMS), despite all the new drugs that are available, diet and lifestyle should remain the first osteoporosis management tool. Only after diet and lifestyle has failed should any of the newly approved treatment options to prevent osteoporosis be considered. […]
A recent study of one man at the Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, The Netherlands combined both treatment modalities, radiopharmaceuticals and bisphosphonates, to combat bone pain caused by bone metastases. Their results were surprising. Bone-seeking radiopharmaceuticals and bisphosphonates are both an indicated treatment for men with prostate cancer when painful [...]